Join us for an informative webinar session exploring the world of liquid biopsy. Discover its applications in non-small cell lung cancer (NSCLC), understand its clinical utility, and explore the challenges it presents. Delve into the latest techniques and technologies used in liquid biopsy, and gain insights into future directions and ongoing research in this dynamic field. Don't miss this opportunity to broaden your knowledge on liquid biopsy and its potential impact on cancer diagnostics and treatment. This webinar offers CMLE credits.
Wednesday 26th July 2023 at 10:00am CEST / 5:00pm KST
Request the recording now
- Diaceutics - Welcome & introduction to Diaceutics.
- Dr. Evans - Liquid biopsy applications in NSCLC & Clinical Utility and Challenges
- Dr. Lee - Liquid Biopsy Techniques and Technologies, and Future Directions and Research
- All participants - Discussion and questions.
Dr. Kyung A-Lee
Dr. Kyung A-Lee is a distinguished professor in the Department of Laboratory Medicine at Gangnam Severance Hospital, affiliated with Yonsei University College of Medicine in Seoul, Korea. With a specialization in Diagnostic Molecular Genetics and Clinical Genomics, Dr. Lee has made remarkable contributions to the field of medical genetics and diagnostics. She currently serves as the President of the Korean Society for Genetic Diagnostics (KSGD), where she leads initiatives to promote excellence in genetic diagnostics and enhance patient care. Dr. Lee holds the position of Director of policy affairs at the Korean Society for Laboratory Medicine (KSLM). In addition, recognized for her expertise in genetic testing, Dr. Lee serves as the Chairman of the audit committee for genetic testing at the prestigious Korean Institute of Genetic Testing Evaluation (KIGTE).
Dr Matthew Evans
Dr Matthew Evans is a consultant Cellular Pathologist at both University Hospital Southampton NHS Foundation Trust and Black Country Pathology Services, where he specialises in biomarker, thoracic and gynaecological pathology. He was recently appointed Pathology Lead for the Central & South Genomic Medicine Service Alliance, and sits on the national Cancer Genomics Test Evaluation Working Group. He is particularly interested in the role of non-NGS testing technologies alongside genomic testing, and in biomarkers predicting response to immune checkpoint inhibitors. He has worked with industry in the roll-out of PD-L1 in multiple tumour types and trained several hundred pathologists globally in PD-L1 assessment.
Sign up to the full series below!
To be included in all the upcoming LabTalks in the Liquid Biopsy series and receive exclusive access to the recordings of previous Liquid Biopsy LabTalks, sign up here.